4.8 Review

Narcolepsy

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 373, 期 27, 页码 2654-2662

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMra1500587

关键词

-

资金

  1. Jazz Pharmaceuticals
  2. Eisai
  3. Vertex Pharmaceuticals
  4. Prexa Pharmaceuticals
  5. Merck

向作者/读者索取更多资源

Narcolepsy, one of the most common causes of chronic sleepiness, affects about 1 in 2000 people. Despite the frequency of narcolepsy, the average time from the onset of symptoms to diagnosis is 5 to 15 years, and narcolepsy may remain undiagnosed in as many as half of all affected people with narcolepsy, since many clinicians are unfamiliar with this disorder. 1 Fortunately, awareness of narcolepsy and other sleep disorders is increasing, and over the past several years researchers have made great progress in understanding narcolepsy. Clinicians now recognize two types of narcolepsy. Type 1 is caused by extensive loss of hypothalamic neurons that produce the neuropeptides orexin-A and -B (also referred to as hypocretin-1 and -2); type 2 includes most of the same symptoms, but its cause is unknown. This review focuses on the symptoms and pathologic and neurobiologic features of narcolepsy and provides a framework for diagnosis and effective treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据